Inhibition of atherosclerosis by angiotensin II type 1 receptor antagonists

American Journal of Cardiovascular Drugs

Volumn 13, Issue 4, 2013, Pages 221-224

  Peters, Stefan ^a  

^a Klinikum Salzgitter GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; BRADYKININ; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN; OLMESARTAN; RAMIPRIL; TELMISARTAN; VALSARTAN;

ACUTE HEART INFARCTION; APOPTOSIS; ATHEROMA; ATHEROSCLEROSIS; COLONY FORMING UNIT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENDOTHELIAL PROGENITOR CELL; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; META ANALYSIS (TOPIC); NEUTROPHIL; NOTE; OXIDATION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOOTH MUSCLE FIBER;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 84880874443     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0017-4     Document Type: Note

References (35)

1. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372-8.
2. Seeger H, Mueck AO, Lippert TH. Effects of valsartan and 17-beta-estradiol on the oxidation of low-density lipoprotein in vitro. Coron Artery Dis. 2000;11:347-9.
3. Raiden S, Giordano M, Andonegui G, et al. Losartan, s selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-formyl-methionyl-leucyl-phenylalanine to neutrophil receptors. J Pharmacol Exp Ther. 1997;281:624-8.
4. Hornig B, Köhler C, Schlink D, et al. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B1-dependent mechanism. Hypertension. 2003;41:1092-6.
5. Volpe M, Paolis P. Angiotensin II AT" subtype receptors: an emerging target for cardiovascular therapy. Ital Heart J. 2000;1:96-103.
6. Ono H, Ishimitsu T. Effects of angiotensin II type 1 and 2 receptor on apoptosis. Nippon Rinsho. 2002;60:1887-92.
7. Yau L, Wilson DP, Werner JP, et al. Bradykinin receptor antagonists attenuate neointimal proliferation postangioplasty. Am J Physiol Heart Circ Physiol. 2001;261:1648-56.
8. Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol. 2010;55:976-82.
9. Hirohata A, Yamamoto K, Miyoshi T, et al. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis. 2012;220:134-8.
10. Ferrario C. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2009;5:301-14.
11. Iwai M, Nakaoka H, Senba I, et al. Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II type 1 receptor blockade on vascular remodelling. Hypertension. 2012;60:137-44.
12. Guerin P, Sauzeau V, Rolli-Derkinderen M, et al. Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin. J Vasc Res. 2005;42:21-8.
13. Cohn JN, Anand IS, Latini R, Valsartan Heart Failure Trial Investigators, et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation. 2003;108:1306-9.
14. Amano T, Matsubara T, Izana H, et al. Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol. 2006;97:785-8.
15. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot Study. Circulation. 1999;100:1056-64.
16. Okada T, Yamamoto H, Okimoto T, et al. Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents. Circ J. 2011;75:1641-8.
17. Okumura M, Iwai M, Ide A, et al. Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression. Hypertension. 2005;46:577-83.
18. Matsuo Y, Imanishi T, Hayashi Y, et al. The effect of senescence of endothelial progenitor cells on in-stent restenosis in patients undergoing coronary stenting. Intern Med. 2006;45:581-7.
19. Bahlmann FH, de Groot K, Mueller O, et al. Stimulation of endothelial progenitor cells. A new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005;45:526-9.
20. Nickenig G, Baumer AT, Grohe C, et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation. 1998;97:2197-201.
21. Anand IS, Latini R, Florea VG, for the Val-HeFT Investigators, et al. C-reactive protein in heart failure, prognostic value and the effect of valsartan. Circulation. 2005;112:1428-34.
22. Ridker PM, Danielson E, Rifai N, Val-MARC Investigators, et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48:73-9.
23. Krämer J, Ruf RG, Schmidt S, et al. The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial - a multicenter study of AT1-receptor blocker therapy in coronary stenting. J Invasive Cardiol. 2008;20:205-10.
24. Yokoyama J, Higuma T, Tomita H, et al. Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril. Int J Cardiol. 2009;132:114-20.
25. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.
26. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-8.
27. Yusuf S, Teo KK, Pogue J, for the ONTARGET Investigators, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
28. Kun X, Yong L, Bo J, et al. Neointimal hyperplasia inhibition effect of angiotensin II type 1 receptor blockers in patients after coronary stent implantation: a meta-analysis. Am J Cardiovasc Drugs. 2011;11:209-13.
29. Peters S, Koehler B, Steffen H, et al. Late lumen loss and follow-up diameter stenosis at different doses of oral valsartan six months after bare-metal stent implantation in type B2/C coronary lesions. Int J Cardiol. 2010;142:29-32.
30. Peters S. Comparison of efficacy of low- (80 mg/d) and high- (160-320 mg/d) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions. Am J Cardiovasc Drugs. 2008;8:83-7.
31. Peters S, Trümmel M, Meyners W, et al. Valsartan versus ACE inhibition after bare metal stent implantation - results of the VALVACE trial. Int J Cardiol. 2005;98:331-5.
32. Peters S, Götting B, Trümmel M, et al. Valsartan for the prevention of restenosis after stenting of type B2/C lesions: the Val-PREST trial. J Invasive Cardiol. 2001;13:93-7.
33. Wakeyama T, Ogawa H, Iida H, et al. Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ J. 2003;67:519-22.
34. Yoshida O, Hirayama H, Nanasato M, et al. The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am Heart J. 2005;149:e2.
35. Iwata A, Miura S, Imazumi S, et al. Valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J. 2007;71:31-8.